Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 149 articles:
HTML format

Single Articles

    July 2022
    NTCP: a pharmacological target for multiple liver conditions.
    Gut. 2022;71:1248-1250.

  2. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.

  3. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    PubMed     Abstract available

    June 2022
  4. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.

  5. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available

    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.

  7. UCHE-ANYA E, Anyane-Yeboa A, Berzin TM, Ghassemi M, et al
    Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
    Gut. 2022 Jun 10. pii: gutjnl-2021-326271. doi: 10.1136/gutjnl-2021-326271.
    PubMed     Abstract available

  8. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.

    May 2022
  9. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    PubMed     Abstract available

  10. DHAR A, Haboubi HN, Attwood SE, Auth MKH, et al
    British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.
    Gut. 2022 May 23. pii: gutjnl-2022-327326. doi: 10.1136/gutjnl-2022-327326.
    PubMed     Abstract available

  11. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
    Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
    PubMed     Abstract available

  12. GONZALEZ-RELLAN MJ, Novoa E, da Silva Lima N, Rodriguez A, et al
    Hepatic p63 regulates glucose metabolism by repressing SIRT1.
    Gut. 2022 May 17. pii: gutjnl-2021-326620. doi: 10.1136/gutjnl-2021-326620.
    PubMed     Abstract available

  13. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
    Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
    Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.

  14. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    PubMed     Abstract available

  15. TAMAKI N, Munaganuru N, Jung J, Yonan AQ, et al
    Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Gut. 2022;71:983-990.
    PubMed     Abstract available

    April 2022
  16. HERNAEZ R, Avila MA
    Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
    Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.

  17. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.

  18. HOHMANN N, Schroder F, Moreira B, Teng H, et al
    Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
    Gut. 2022;71:842-844.

  19. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
    Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
    Gut. 2022;71:807-821.
    PubMed     Abstract available

  20. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022;71:778-788.
    PubMed     Abstract available

    March 2022
  21. ZHANG C, Li J, Cheng Y, Meng F, et al
    Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.
    Gut. 2022 Mar 31. pii: gutjnl-2021-325915. doi: 10.1136/gutjnl-2021-325915.
    PubMed     Abstract available

  22. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.

  23. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    PubMed     Abstract available

  24. RHA MS, Han JW, Koh JY, Lee HS, et al
    Impaired antibacterial response of liver sinusoidal Vgamma9(+)Vdelta2(+) T cells in patients with chronic liver disease.
    Gut. 2022;71:605-615.
    PubMed     Abstract available

    February 2022
  25. LU LG, Zhou ZL, Wang XY, Liu BY, et al
    PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326350. doi: 10.1136/gutjnl-2021-326350.
    PubMed     Abstract available

  26. SUN S, Yang Q, Zhou Q, Cao W, et al
    Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study.
    Gut. 2022;71:443-445.

  27. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.

  28. FRANCQUE S, Wong VW
    NAFLD in lean individuals: not a benign disease.
    Gut. 2022;71:234-236.

  29. YOUNES R, Govaere O, Petta S, Miele L, et al
    Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Gut. 2022;71:382-390.
    PubMed     Abstract available

  30. TREBICKA J, Gu W, de Ledinghen V, Aube C, et al
    Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease.
    Gut. 2022;71:402-414.
    PubMed     Abstract available

    January 2022
  31. SONDERGAARD JN, Sommerauer C, Atanasoai I, Hinte LC, et al
    CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325109. doi: 10.1136/gutjnl-2021-325109.
    PubMed     Abstract available

  32. JI F, Zhang J, Liu N, Gu Y, et al
    Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.
    Gut. 2022 Jan 7. pii: gutjnl-2021-326050. doi: 10.1136/gutjnl-2021-326050.
    PubMed     Abstract available

  33. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.

  34. MEZZANO G, Juanola A, Cardenas A, Mezey E, et al
    Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
    Gut. 2022;71:148-155.
    PubMed     Abstract available

  35. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
    Gut. 2022;71:156-162.
    PubMed     Abstract available

    December 2021
  36. VITALE A, Svegliati-Baroni G, Ortolani A, Cucco M, et al
    Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Gut. 2021 Dec 21. pii: gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915.
    PubMed     Abstract available

  37. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    PubMed     Abstract available

  38. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.

  39. BANG JY, Ward TJ, Guirguis S, Krall K, et al
    Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
    Gut. 2021;70:2224-2226.

  40. ARNORIAGA-RODRIGUEZ M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, et al
    Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways.
    Gut. 2021;70:2283-2296.
    PubMed     Abstract available

  41. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    PubMed     Abstract available

  42. CARGILL Z, Cargill T, Lei B, Bekkali N, et al
    Uphill or downhill bleeding?
    Gut. 2021;70:2282-2348.

    November 2021
  43. LIU DS, Frampton AE
    Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
    Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.

    October 2021
  44. TRAUNER M, Fuchs CD
    Novel therapeutic targets for cholestatic and fatty liver disease.
    Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
    PubMed     Abstract available

  45. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Gut. 2021;70:e7.

  46. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
    Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Gut. 2021;70:1925-1932.
    PubMed     Abstract available

  47. LIU T, Tan J, Wu M, Fan W, et al
    High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells.
    Gut. 2021;70:1965-1977.
    PubMed     Abstract available

  48. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    PubMed     Abstract available

  49. MANKA P, Baba HA, Wedemeyer H, Kahraman A, et al
    Diet-refractory NASH in an elderly woman.
    Gut. 2021;70:1924-1945.

    September 2021
  50. AN J, Kim HI, Oh B, Oh YJ, et al
    Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
    Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.

  51. JACHS M, Hartl L, Schaufler D, Desbalmes C, et al
    Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Gut. 2021;70:1758-1767.
    PubMed     Abstract available

    August 2021
  52. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    PubMed     Abstract available

  53. LIU J, Geng W, Sun H, Liu C, et al
    Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
    PubMed     Abstract available

  54. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
    The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
    Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
    PubMed     Abstract available

    July 2021
  55. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    PubMed     Abstract available

  56. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    PubMed     Abstract available

  57. WRZOSEK L, Ciocan D, Hugot C, Spatz M, et al
    Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
    Gut. 2021;70:1299-1308.
    PubMed     Abstract available

    June 2021
  58. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.

  59. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.

    May 2021
  60. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available

  61. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.

  62. MANTOVANI A, Petracca G, Beatrice G, Tilg H, et al
    Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Gut. 2021;70:962-969.
    PubMed     Abstract available

    April 2021
  63. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    PubMed     Abstract available

  64. YADAV DK, Singh A, Zhang Q, Bai X, et al
    Involvement of liver in COVID-19: systematic review and meta-analysis.
    Gut. 2021;70:807-809.

  65. WANG X, He Y, Mackowiak B, Gao B, et al
    MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
    Gut. 2021;70:784-795.
    PubMed     Abstract available

  66. ZHANG X, Coker OO, Chu ES, Fu K, et al
    Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Gut. 2021;70:761-774.
    PubMed     Abstract available

    March 2021
  67. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.

  68. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.

  69. SAPENA V, Enea M, Torres F, Celsa C, et al
    Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
    Gut. 2021 Mar 19. pii: gutjnl-2020-323663. doi: 10.1136/gutjnl-2020-323663.
    PubMed     Abstract available

  70. ZHAN K, Liao S, Li J, Bai Y, et al
    Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation.
    Gut. 2021;70:628-629.

  71. KIM DH, Hong SB, Choi SH, Kim SY, et al
    Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323615. doi: 10.1136/gutjnl-2020-323615.

  72. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
    Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
    Gut. 2021;70:585-594.
    PubMed     Abstract available

    February 2021
  73. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    PubMed     Abstract available

  74. CHEN HN, Shu Y, Liao F, Liao X, et al
    Genomic evolution and diverse models of systemic metastases in colorectal cancer.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323703. doi: 10.1136/gutjnl-2020-323703.
    PubMed     Abstract available

  75. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
    Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
    Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
    PubMed     Abstract available

  76. GOESER F, Munch P, Lesker TR, Lutz PL, et al
    Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
    Gut. 2021;70:438-440.

  77. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    PubMed     Abstract available

    January 2021
  78. YASKOLKA MEIR A, Rinott E, Tsaban G, Zelicha H, et al
    Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial.
    Gut. 2021 Jan 18. pii: gutjnl-2020-323106. doi: 10.1136/gutjnl-2020-323106.
    PubMed     Abstract available

  79. AOKI S, Inoue K, Klein S, Halvorsen S, et al
    Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
    Gut. 2021 Jan 11. pii: gutjnl-2020-322493. doi: 10.1136/gutjnl-2020-322493.
    PubMed     Abstract available

  80. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.

  81. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.

  82. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
    LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
    Gut. 2021;70:180-193.
    PubMed     Abstract available

  83. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
    Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
    Gut. 2021;70:170-179.
    PubMed     Abstract available

    December 2020
  84. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    PubMed     Abstract available

  85. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    PubMed     Abstract available

  86. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    PubMed     Abstract available

    November 2020
  87. SUN N, Shen C, Zhang L, Wu X, et al
    Hepatic Kruppel-like factor 16 (KLF16) targets PPARalpha to improve steatohepatitis and insulin resistance.
    Gut. 2020 Nov 30. pii: gutjnl-2020-321774. doi: 10.1136/gutjnl-2020-321774.
    PubMed     Abstract available

  88. CALDERARO J, Kather JN
    Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322880. doi: 10.1136/gutjnl-2020-322880.
    PubMed     Abstract available

  89. KOH EH, Yoon JE, Ko MS, Leem J, et al
    Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis.
    Gut. 2020 Nov 18. pii: gutjnl-2020-322509. doi: 10.1136/gutjnl-2020-322509.
    PubMed     Abstract available

  90. HAO L, Zhong W, Dong H, Guo W, et al
    ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis.
    Gut. 2020 Nov 11. pii: gutjnl-2020-321548. doi: 10.1136/gutjnl-2020-321548.
    PubMed     Abstract available

  91. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
    Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
    Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
    PubMed     Abstract available

    Keeping the liver fit with TREM2 during hepatic carcinogenesis.
    Gut. 2020 Nov 4. pii: gutjnl-2020-322638. doi: 10.1136/gutjnl-2020-322638.

  93. SHANG R, Song X, Wang P, Zhou Y, et al
    Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Gut. 2020 Nov 3. pii: gutjnl-2020-320716. doi: 10.1136/gutjnl-2020-320716.
    PubMed     Abstract available

  94. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.

    October 2020
  95. BAYO J, Fiore EJ, Dominguez LM, Cantero MJ, et al
    Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Gut. 2020 Oct 26. pii: gutjnl-2020-321454. doi: 10.1136/gutjnl-2020-321454.
    PubMed     Abstract available

  96. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.

  97. TILG H, Targher G
    NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought.
    Gut. 2020 Oct 19. pii: gutjnl-2020-323188. doi: 10.1136/gutjnl-2020-323188.

  98. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    PubMed     Abstract available

  99. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    PubMed     Abstract available

  100. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.

  101. ZHANG N, Jiang W, Zhang Y, Song TQ, et al
    Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria.
    Gut. 2020;69:1893-1895.

  102. DE TONI EN
    Immune checkpoint inhibitors: use them early, combined and instead of TACE?
    Gut. 2020;69:1887-1888.

  103. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    PubMed     Abstract available

  104. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    PubMed     Abstract available

    September 2020
  105. SHI JY, Wang X, Ding GY, Dong Z, et al
    Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.
    Gut. 2020 Sep 30. pii: gutjnl-2020-320930. doi: 10.1136/gutjnl-2020-320930.
    PubMed     Abstract available

  106. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    PubMed     Abstract available

  107. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available

  108. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.

  109. VON FELDEN J, Garcia-Lezana T, Schulze K, Losic B, et al
    Liquid biopsy in the clinical management of hepatocellular carcinoma.
    Gut. 2020 Sep 3. pii: gutjnl-2019-320282. doi: 10.1136/gutjnl-2019-320282.
    PubMed     Abstract available

  110. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    PubMed     Abstract available

  111. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.

    August 2020
  112. SHARMA S, Elhence A, Vaishnav M, Kumar R, et al
    COVID-19 in patients with cirrhosis: understanding adverse impact.
    Gut. 2020 Aug 21. pii: gutjnl-2020-322561. doi: 10.1136/gutjnl-2020-322561.

  113. YAMAMOTO A, Kawada N, Jogo A, Murai K, et al
    Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein.
    Gut. 2020 Aug 18. pii: gutjnl-2020-322367. doi: 10.1136/gutjnl-2020-322367.

  114. YANG H, Sun L, Mao Y
    Response letter to: letter to the editor: three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Aug 14. pii: gutjnl-2020-322471. doi: 10.1136/gutjnl-2020-322471.

  115. PINTER M, Scheiner B, Peck-Radosavljevic M
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Gut. 2020 Aug 3. pii: gutjnl-2020-321702. doi: 10.1136/gutjnl-2020-321702.
    PubMed     Abstract available

  116. BOLLIPO S, Kapuria D, Rabiee A, Ben-Yakov G, et al
    One world, one pandemic, many guidelines: management of liver diseases during COVID-19.
    Gut. 2020;69:1369-1372.

  117. TARGHER G, Mantovani A, Byrne CD, Wang XB, et al
    Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
    Gut. 2020;69:1545-1547.

  118. RADU P, Dufour JF
    Changing TACTICS in intermediate HCC: TACE plus sorafenib.
    Gut. 2020;69:1374-1376.

  119. TILG H, Burcelin R, Tremaroli V
    Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis?
    Gut. 2020;69:1373-1374.

  120. JOHNSTON M, Cook C, Buchanan RM
    RE: Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial.
    Gut. 2020;69:1536-1537.

    July 2020
  121. KAUR S, Tripathi DM, Ghosh S
    Three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Jul 21. pii: gutjnl-2020-322317. doi: 10.1136/gutjnl-2020-322317.

  122. BAJAJ JS, Garcia-Tsao G, Biggins S, Kamath PS, et al
    Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
    Gut. 2020 Jul 13. pii: gutjnl-2020-322118. doi: 10.1136/gutjnl-2020-322118.
    PubMed     Abstract available

  123. WEBER S, Mayerle J, Irlbeck M, Gerbes AL, et al
    Severe liver failure during SARS-CoV-2 infection.
    Gut. 2020;69:1365-1367.

  124. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.

    June 2020
  125. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.

  126. THANGAPANDI VR, Knittelfelder O, Brosch M, Patsenker E, et al
    Loss of hepatic Mboat7 leads to liver fibrosis.
    Gut. 2020 Jun 26. pii: gutjnl-2020-320853. doi: 10.1136/gutjnl-2020-320853.
    PubMed     Abstract available

  127. STENGEL S, Steube A, Kose-Vogel N, Kirchberger-Tolstik T, et al
    Primed circulating monocytes are a source of IL-1beta in patients with cirrhosis and ascites.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321597. doi: 10.1136/gutjnl-2020-321597.

  128. BECCHETTI C, Zambelli MF, Pasulo L, Donato MF, et al
    COVID-19 in an international European liver transplant recipient cohort.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321923. doi: 10.1136/gutjnl-2020-321923.
    PubMed     Abstract available

    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.

  130. BAYARD Q, Nault JC, Zucman-Rossi J
    RSPO2 abnormal transcripts result from read-through in liver tumours with high ss-catenin activation and CTNNB1 mutations.
    Gut. 2020;69:1152-1153.

  131. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    PubMed     Abstract available

  132. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    PubMed     Abstract available

    May 2020
  133. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.

  134. YANG H, Sun L, Pang Y, Hu D, et al
    Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure.
    Gut. 2020 May 20. pii: gutjnl-2019-319960. doi: 10.1136/gutjnl-2019-319960.
    PubMed     Abstract available

  135. NATHANI P, Gopal P, Rich N, Yopp A, et al
    Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis.
    Gut. 2020 May 12. pii: gutjnl-2020-321040. doi: 10.1136/gutjnl-2020-321040.
    PubMed     Abstract available

  136. DUFOUR JF, Caussy C, Loomba R
    Combination for therapy non-alcoholic steatohepatitis: rationale, opportunities and challenges.
    Gut. 2020 May 7. pii: gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.
    PubMed     Abstract available

    April 2020
  137. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.

  138. MONTEIRO S, Grandt J, Uschner FE, Kimer N, et al
    Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2020 Apr 2. pii: gutjnl-2019-320170. doi: 10.1136/gutjnl-2019-320170.
    PubMed     Abstract available

  139. CINNAMON E, Pikarsky E
    Are we ready for targeted therapy combinations in HCC?
    Gut. 2020;69:613-614.

  140. AVILA MA, Dufour JF, Gerbes AL, Zoulim F, et al
    Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.
    Gut. 2020;69:764-780.
    PubMed     Abstract available

  141. LA BELLA T, Imbeaud S, Peneau C, Mami I, et al
    Adeno-associated virus in the liver: natural history and consequences in tumour development.
    Gut. 2020;69:737-747.
    PubMed     Abstract available

  142. NATHWANI R, Mullish BH, Kockerling D, Rajani N, et al
    Recurrent bacteraemia following variceal haemorrhage.
    Gut. 2020;69:726-780.

    March 2020
  143. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed     Abstract available

  144. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available

  145. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed     Abstract available

    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.

    February 2020
  147. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available

    January 2020
  148. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available

    December 2019
  149. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.